CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II.
Fiche du document
2006
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/sj.bjc.6603322
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/16940980
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/0007-0920
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B1D3188290392
info:eu-repo/semantics/restrictedAccess , Restricted: indefinite embargo , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
RecurrenceCiter ce document
V. Voelter et al., « CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II. », Serveur académique Lausannois, ID : 10.1038/sj.bjc.6603322
Métriques
Partage / Export
Résumé
Patients with rectal cancer are at high risk of disease recurrence despite neoadjuvant radiochemotherapy with 5-Fluorouracil (5FU), a regimen that is now widely applied. In order to develop a regimen with increased antitumour activity, we previously established the recommended dose of neoadjuvant CPT-11 (three times weekly 90 mg m(-2)) concomitant to hyperfractionated accelerated radiotherapy (HART) followed by surgery within 1 week. Thirty-three patients (20 men) with a locally advanced adenocarcinoma of the rectum were enrolled in this prospective phase II trial (1 cT2, 29 cT3, 3 cT4 and 21 cN+). Median age was 60 years (range 43-75 years). All patients received all three injections of CPT-11 and all but two patients completed radiotherapy as planned. Surgery with total mesorectal excision (TME) was performed within 1 week (range 2-15 days). The preoperative chemoradiotherapy was overall well tolerated, 24% of the patients experienced grade 3 diarrhoea that was easily manageable. At a median follow-up of 2 years no local recurrence occurred, however, nine patients developed distant metastases. The 2-year disease-free survival was 66% (95% confidence interval 0.48-0.83). Neoadjuvant CPT-11 and HART allow for excellent local control; however, distant relapse remains a concern in this patient population.